Forxiga (dapagliflozin) 5mg should no longer be used for the treatment of Type 1 Diabetes Mellitus
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Forxiga
|
| Active substance |
dapagliflozin propanediol monohydrate
|
| Therapeutic area (MeSH) |
Diabetes Mellitus, Type 2
|
| Procedure number |
EMEA/H/C/002322/II/0071
|
| Regulatory outcome |
Variation
|
| DHPC type |
Type II variation
|
| Human ATC code |
A10BK01
|
| Dissemination date |
11/11/2021
|